NCT06109870 Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
| NCT ID | NCT06109870 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | HPV |
| Study Type | INTERVENTIONAL |
| Enrollment | 920 participants |
| Start Date | 2023-10-30 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 920 participants in total. It began in 2023-10-30 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.
Eligibility Criteria
Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: * Provision of signed and dated informed consent form * Currently resident in RGV or other low-resource community in Texas * Stated willingness to comply with all study procedures * Females; Age ≥25 years * Have no history of hysterectomy with removal of the cervix * Have no history of cervical cancer or high-grade dysplasia * Have not had a Pap test in the past 3.5 years or Pap/HPV co-test in the past 5.5 years. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Unable to communicate in English or Spanish * Lack valid telephone contact information * Report being currently pregnant.
Contact & Investigator
Jane Montealegre, M D
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06109870 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HPV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06109870 currently recruiting?
Yes, NCT06109870 is actively recruiting participants. Contact the research team at jrmontealegre@mdanderson.org for enrollment information.
Where is the NCT06109870 trial being conducted?
This trial is being conducted at Austin, United States, Houston, United States.
Who is sponsoring the NCT06109870 clinical trial?
NCT06109870 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Jane Montealegre, M D at M.D. Anderson Cancer Center. The trial plans to enroll 920 participants.